Companies try different plans for same clotting factor product.
作者信息
Thompson C A
出版信息
Am J Health Syst Pharm. 2001 Jan 1;58(1):16, 20. doi: 10.1093/ajhp/58.1.16.
PMID:11194129
Abstract
摘要
相似文献
1
Companies try different plans for same clotting factor product.
Am J Health Syst Pharm. 2001 Jan 1;58(1):16, 20. doi: 10.1093/ajhp/58.1.16.
2
Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.
Transfus Med Rev. 1992 Oct;6(4):277-9. doi: 10.1016/s0887-7963(92)70182-5.
3
rFactor VIII deficit questioned.
Nat Biotechnol. 2000 Nov;18(11):1133. doi: 10.1038/81098.
4
Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Wis Med J. 1982 Feb;81(2):28-31.
5
A regional redistribution programme for the optimal management of clotting factor concentrates prescribed by haemophilia treatment centres.
Transfus Med. 2013 Oct;23(5):370-2. doi: 10.1111/tme.12047. Epub 2013 Jun 13.
6
Benefits associated with a broad selection of dosage strengths for recombinant factor VIII products.
Haemophilia. 2012 Mar;18(2):182-6. doi: 10.1111/j.1365-2516.2011.02627.x. Epub 2011 Aug 4.
7
Obtention production and use of factor VIII in Costa Rica.
Scand J Haematol Suppl. 1984;40:509-11. doi: 10.1111/j.1600-0609.1984.tb02610.x.
8
Coagulation factor VIII concentrates and the marketplace.
Lancet. 1988 Jun 4;1(8597):1270. doi: 10.1016/s0140-6736(88)92083-1.
9
To what extent can plasma supply for factor VIII production, be obtained within the frame of a blood component program?
Scand J Haematol Suppl. 1984;40:485-90. doi: 10.1111/j.1600-0609.1984.tb02606.x.
10
Recombinant clotting factors in the treatment of hemophilia.
Thromb Haemost. 1999 Aug;82(2):516-24.
Zotero 插件